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Dominant Role of the ERAP1 Polymorphism R528K in
Shaping the HLA–B27 Peptidome Through Differential
Processing Determined by Multiple Peptide Residues
Alejandro Sanz-Bravo,1 Jose´ Campos,2 Marina S. Mazariegos,3 and Jose´ A. Lo´pez de Castro1
Objective. To characterize the alterations, as well
as their mechanisms, induced in the HLA–B27–bound
peptidome expressed in live cells by the natural ERAP1
polymorphisms predisposing to ankylosing spondylitis
(AS): R528K and N575D/Q725R.
Methods. HLA–B*27:05–bound peptides were iso-
lated from 3 human lymphoid cell lines expressing
distinct ERAP1 variants differing at residues 528 and/or
575/725. The high-performance liquid chromatography–
fractionated peptide pools were compared by mass
spectrometry based on identity of molecular mass and
chromatographic retention time. The relative amount of
each shared peptide in any given cell line pair was
estimated from the respective ion peak intensities. Pep-
tide sequencing was also carried out by mass spectrom-
etry.
Results. HLA–B27–bound ligands predominant
in the context of the ERAP1 variant with K528 collec-
tively showed higher molecular mass, higher frequency
of N-terminal residues resistant to ERAP1, and bulkier
residues downstream of the N-terminus, relative to
peptides predominant in the R528 context. None of
these differences were observed with ERAP1 variants
differing at positions 575/725, but not at residue 528.
Neither R528K nor N575D/Q725R altered the mean
length of B*27:05-bound ligands.
Conclusion. The R528K, but not the N575D/
Q725R, polymorphism alters the expression levels of
many HLA–B*27:05–bound peptides, depending on the
susceptibility of their N-terminal residues to trimming
and depending on the size of the amino acid side chains
at multiple positions downstream of the N-terminus.
The significant alterations in the B*27:05 peptidome
and the structural features of the peptides that deter-
mine their differential expression in distinct ERAP1
contexts account for the association of the R528K
polymorphism with AS.
Endoplasmic reticulum aminopeptidase 1
(ERAP1) is one of the main non–major histocompati-
bility complex (non-MHC) susceptibility factors in an-
kylosing spondylitis (AS) among individuals positive for
HLA–B27 (1,2), accounting for 26% of the population-
attributable risk (3). ERAP1 trims peptides in the
endoplasmic reticulum to the optimal length, 9–10 res-
idues, for MHC class I binding (4,5). A unique property
of this molecule is that its activity is strongly dependent
on substrate length, so that trimming essentially stops
when the peptide reaches 8 residues (6). Crystallo-
graphic studies (7,8) revealed that this feature is due to
the fact that the peptide substrate binds in a cavity that
is spatially distinct from the catalytic site. Occupancy of
the substrate-binding site induces a conformational re-
arrangement that is critical for peptide trimming. Thus,
ERAP1 polymorphisms can affect enzymatic activity by
altering the catalytic site, the substrate-binding site, or
the conformational transition to the active state.
The epistatic association of ERAP1 and HLA–
B27 in AS, which also holds for other MHC class
I–associated diseases (9,10), together with the observa-
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tion that AS-associated ERAP1 polymorphisms affect
the enzymatic activity (for review, see ref. 11), suggest
that the association of ERAP1 with AS is due to its
effects on the HLA–B27 peptidome. The consequences
of these effects are not necessarily limited to altering
antigen presentation, since large changes in the pep-
tidome may affect other features of HLA–B27, such as
folding and stability, which are also peptide-dependent
and potentially pathogenic (12). Indeed, AS-associated
ERAP1 polymorphism was shown to substantially alter
the peptidome and thermostability of B*27:04 (13). That
study addressed the joint effect of multiple co-occurring
changes, but not of individual ones. The complex influ-
ence of the natural ERAP1 haplotypes on peptide
processing was revealed in a recent study in which
several ERAP1 variants were compared for their trim-
ming of N-terminally extended precursors of a model
peptide (14). Yet, genetic studies showed that the asso-
ciation of ERAP1 with AS fits a 2-mutation model in
which both K528R and D575N/R725Q protect from AS.
Among HLA–B27–positive individuals, those homozy-
gous for the protective ERAP1 variants at both positions
are 3–4 times less susceptible to AS than those carrying
the corresponding predisposing alleles (2).
In the present study, we aimed to determine the
effects of these AS-associated ERAP1 polymorphisms
on the constitutive B*27:05 peptidome in live cells. Our
strategy focused on alterations in peptide amounts oc-
curring in distinct ERAP1 contexts, rather than on the
presence or absence of specific epitopes, since failure to
detect a peptide is not proof of its absence. Through an
appropriate choice of the ERAP1 background of B*27:
05-positive cell lines, we separately assessed the role of
the K528R and D575N/R725Q changes on shaping the
B*27:05 peptidome. The mechanism underlying these
effects was determined by comparing the structural
features of the peptides presented in the various ERAP1
contexts.
MATERIALS AND METHODS
Cell lines. P50 (HLA–A*23, *24, B*27:05, *14,
C*02,*08) and LG2 (HLA–A*02, B*27:05, C*01) are Epstein-
Barr virus (EBV)–transformed lymphoblastoid cell lines. C1R-
B*27:05 (C1R05) is a transfectant of the lymphoid HLA class
I–defective Hmy2.C1R cell line (15), expressing B*27:05 (16).
Cells were cultured in RPMI 1640 medium supplemented with
2 mM L-glutamine and 10% fetal bovine serum (Invitrogen).
Genomic sequencing and Western blotting. The se-
quence of ERAP1 in C1R cells has been previously reported
(13). Exons 2–20 of ERAP1 in LG2 cells, encompassing the
coding region of the mature protein, and the same exons
(except for exons 3, 14, and 16) in P50 cells were separately
amplified via polymerase chain reaction and sequenced using
the same procedure. For ERAP2, the AS-associated polymor-
phisms at codon 392 (rs2549782, exon 7) and at the exon 10
splice site (rs2248374), which are in strong linkage disequili-
brium, were determined by genomic sequencing. The latter
polymorphism affects ERAP2 expression (17). The rs9901869
polymorphism, which was used to establish AS association of
the NPEPPS gene, which codes for the puromycin-sensitive
aminopeptidase (18), was also sequenced. ERAP1 and ERAP2
protein levels were determined by Western blotting of whole
lysates of 5  105 cells as described elsewhere (13), except that
electroblotting was performed at 80V for 80 minutes.
Isolation of HLA–B27–bound peptides. HLA–B27–
bound peptides were isolated as previously described (19).
Briefly, 1010 cells were lysed in 1% Igepal CA-630 with a
mixture of protease inhibitors (Roche). The soluble fraction
was subjected to affinity chromatography using ME1 (IgG1),
an anti–HLA–B7/B27/B22 monoclonal antibody that recog-
nizes the bulk of HLA–B27–peptide complexes (20). HLA–
B27–bound peptides were eluted with 0.1% trifluoroacetic
acid, filtered, concentrated, and subjected to fractionation by
high-performance liquid chromatography (HPLC) at a flow
rate of 100 l/minute, as described elsewhere (21). Fractions of
50 l were collected and stored at 20°C.
Mass spectrometry (MS). Analysis of individual HPLC
fractions by matrix-assisted laser desorption ionization–time-
of-flight (MALDI-TOF) MS and peptide sequencing of the
most prominent ion peaks in each fraction by MALDI-TOF/
TOF MS/MS were carried out using a 4800 Proteomics Ana-
lyzer (Applied Biosystems) as described elsewhere (22). The
MALDI-TOF MS spectra were acquired in reflector-positive
mode at 25 kV in the mass-to-charge (m/z) range of 800–2000,
using a signal-to-noise ratio cutoff of 3, and were processed
using Data Explorer software version 4.9 (Applied Biosys-
tems). Sample handling and acquisition parameters were
tightly controlled to minimize differences among the samples
to be compared in each experiment. Automated comparison of
the MALDI-TOF MS spectra corresponding to correlative
HPLC fractions from different cell lines was performed using
MShandler software as previously described (13).
Susceptibility of N-terminal residues to ERAP1 trim-
ming. We estimated the susceptibility of N-terminal residues
to ERAP1 trimming by assigning a score ranging from 0 to 100
to each amino acid, based on a previously reported assay (23),
as described elsewhere (13). Proline and any residue immedi-
ately preceding proline were assigned a score of 0.
RESULTS
Expression of ERAP1/ERAP2 variants in B*27:
05-positive cell lines. The ERAP1 variant in LG2
showed 5 AS-predisposing polymorphisms, whereas the
one in P50 had the corresponding protective changes.
The ERAP1 variant in C1R05 carried 3 AS-associated
changes (at positions 349, 575, and 725), and 2 protective
changes (at positions 127 and 528). All 3 cell lines had
the AS-protective residue E730 and were homozygous at
all of the polymorphic ERAP1 and ERAP2 positions,
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except for P50. They were genotypically concordant at
the NPEPPS marker rs9901869 (Table 1).
ERAP1 protein expression was 2-fold and
3-fold higher in P50 and LG2 cells, respectively, than in
C1R05 cells (Figure 1A). The high ERAP1 expression in
LG2 reflects a general phenomenon whereby there is a
consistently higher expression of ERAP1 variants carry-
ing the AS-associated polymorphism K528 (24,25).
ERAP2 protein levels were similar in the 3 cell lines
(Figure 1B).
Dominant role of the K528R polymorphism in
altering the B*27:05 peptidome. The B*27:05-bound
peptide pools from LG2, P50, and C1R05 cells were
isolated after immunopurification of HLA–B27 and acid
extraction, were HPLC-fractionated under identical
conditions and consecutive runs, and each fraction was
analyzed by MALDI-TOF MS. The peptide pools were
compared by matching the ion peaks with the same
retention time and m/z. These were considered identical
peptides and were confirmed in all cases in which such
peaks were sequenced from distinct cell lines (see Sup-
plementary Table 1, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38980/abstract).
Three pairwise comparisons were carried out:
LG2/P50, LG2/C1R05, and C1R05/P50. The 2 former
comparisons were aimed at determining the effect of 2
distinct combinations of ERAP1 polymorphisms, both
including the K528R mismatch. C1R05/P50 allowed us
to assess the effect of polymorphisms other than the one
Table 1. ERAP1 and ERAP2 polymorphism in B*27:05-positive cell lines*
SNP Exon
Nucleotide/
aa residue
Consensus
sequence
Cell line
LG2 C1R P50
ERAP1
rs26653 2 380/127 g/R† g/R† c/P c/P
rs26618 5 828/276 a/I a/I g/M a/I
rs27895 6 1037/346 g/G g/G g/G g/G
rs2287987 6 1045/349 a/M† a/M† a/M† g/V
rs30187 11 1583/528 a/K† a/K† g/R g/R
rs10050860 12 1723/575 g/D† g/D† g/D† a/N
rs17482078 15 2174/725 g/R† g/R† g/R† a/Q
rs27044 15 2188/730 c/Q† g/E g/E g/E
ERAP2
rs2549782 7 1176/392 g/K† g/K† g/K† g†,t/K†,N
rs2248374 10 1575/– a† a† a† a†,g
NPEPPS
rs9901869 – – – g g g
* Changes in the coding or forward strands are shown. The nucleotide/amino acid (aa) residue numbering
and consensus sequence are from human ERAP1 isoform 2 (accession no. Q9NZ08-2) and ERAP2
isoform 1 (accession no. Q6P179-1). Single-nucleotide polymorphism (SNP) rs9901869 (a/g) is located in
an intergenic region. All polymorphic positions were determined by genomic sequencing. The ERAP1
sequence from C1R cells has been previously reported (13) and is shown here for comparison only.
Although genotyping of the ERAP2 polymorphism rs2549782 at codon 392 previously suggested
heterozygocity of C1R (13), genomic sequencing in the present study revealed that this cell line is actually
homozygous both at that SNP (gg) and at the linked one, rs2248374.
† SNP associated with an increased risk of ankylosing spondylitis (3,18,24).
Figure 1. Western blot analysis of endoplasmic reticulum aminopep-
tidase 1 (ERAP1) and ERAP2 protein expression. The expression of
ERAP1 (A) and ERAP2 (B) in the LG2, P50, and C1R cell lines was
determined by Western blotting. -tubulin was used as a loading
control. Results from a representative experiment (top) are shown,
along with data from 3 independent analyses (bottom). Numbers
inside the bars are the values represented by the bars. Values are the
mean  SD.
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at residue 528, including D575N/R725Q (Table 1). Each
comparison was carried out 2 or 3 times. As a control,
the B*27:05 peptide pools from 2 independent prepara-
tions of C1R05 cells were compared (see Supplementary
Table 2, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38980/abstract). The methodology used for these
comparisons has been previously described (13).
Peptides shared among any 2 cell lines were
classified according to the relative intensity of the cor-
responding ion peak in both cell lines, designated as the
intensity ratio (IR), in 3 subsets: IR 3-fold, IR 1.5–
3-fold, and IR 1–1.5-fold intensity in one cell line
relative to the other. This was based on the assumption
that the differential effects of ERAP1 polymorphism on
peptide expression would be best revealed among pep-
tides showing the largest disparity in their amounts
between the cell lines being compared. The molecular
weight distribution of the peptides in each subset from
one cell line was compared with the corresponding
subset in the other cell line (Figure 2). A total of
6,000–7,000 shared peptides were detected in each
comparison. They showed Gaussian molecular weight
distributions with mean values of1160–1180 daltons in
all cases. Two distinct patterns were observed.
In the LG2/P50 and LG2/C1R05 comparisons,
the peptides with an IR of 3 in LG2 cells showed a
shift in the molecular weight distribution curve toward
larger values relative to the peptides with an IR of 3 in
either the P50 or C1R05 cell lines (Figures 2A and B).
The mean molecular weight of LG2-derived peptides in
this subset was 52 and 59 daltons higher than the
corresponding values for P50 and C1R05, respectively. A
more attenuated difference was observed for the peptide
subsets with an IR of1.5–3 in both comparisons, which
was close to the background levels in the C1R05/C1R05
control (Supplementary Table 2, available on the Arthri-
tis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.38980/abstract). For peptides with
similar IR (1–1.5), virtually no differences were ob-
served (Figures 2A and B). These results indicate that
B*27:05-bound peptides predominate in LG2, relative to
P50 or C1R05, and have higher molecular weights than
those that predominate in any of these cell lines, relative
Figure 2. Size distribution of B*27:05 ligands as a function of their relative abundance in various ERAP1 contexts. Shared peptides were classified
according to the intensity ratio (IR) of one cell line relative to the other: 3-fold, 1.5–3-fold, and 1–1.5-fold. Results for the LG2/P50 (A), the
LG2/C1R05 (B), and the C1R05/P50 (C) cell line comparisons are shown. The left histogram shows the molecular weight distribution of shared
ligands detected for the 2 cell lines (7,075, 6,953, and 6,204 respectively). The other 3 histograms compare the molecular weight distribution of the
peptide sets by IR subgroup. The difference in the mean molecular weight (MW) between the peptide subsets compared is indicated in each
histogram. Data are from a representative experiment of those shown in Supplementary Table 2 (available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.38980/abstract).
ERAP1 POLYMORPHISM AND THE HLA–B*27:05 PEPTIDOME 695
to LG2. In contrast, no differences in molecular weight
were observed between C1R05 and P50 for any of the IR
ranges (Figure 2C and Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38980/abstract). That
the differences were observed mainly in the IR 3
subsets suggests that many HLA–B27 ligands either
bypass ERAP1 processing or both their generation and
destruction are concomitantly affected by ERAP1 poly-
morphism, resulting in similar epitope amounts with
distinct variants, as previously reported (26).
ERAP1 in LG2 differs from the P50 and C1R
variants at residues 127 and 528, whereas the 3 latter cell
lines are identical at both positions (Table 1). Thus, the 127
and/or 528 polymorphisms are responsible for the molec-
ular weight differences observed. Since K528R, but not
R127P, is known to affect ERAP1 activity (27), most of the
alterations in the B*27:05 peptidome between LG2 and
P50 or C1R05 are probably due to residue 528. In contrast,
the 4 amino acid differences between the ERAP1 variants
of C1R and P50 (Table 1) had no detectable effect on the
MW of the B*27:05 ligands.
N-terminal residues of HLA–B27 ligands as deter-
minants of the effect of ERAP1 variants on the B*27:05-
bound peptidome. If the alterations in the B*27:05 pep-
tidome described above are due to the different enzymatic
activity of ERAP-1 in each cell line, one would expect that
those peptides predominant in cells expressing distinct
ERAP1 variants may differ in the susceptibility of their
flanking and/or P1 residues to trimming. Thus, for each
pairwise comparison, the sequence of 50–100 peptides
from each IR subset of both cell lines was obtained, up to
a total of 470 nonredundant sequences (Supplementary
Table 1, available on the Arthritis & Rheumatology web site
at http://onlinelibrary.wiley.com/doi/10.1002/art.38980/
abstract), of which 296 were previously known HLA–B27
ligands (28).
For these analyses, the peptides were subdivided
into 2 groups: those with an IR of 3 and those with an
IR of 1–3. The susceptibility of the 2 N-terminal
flanking residues (P-2 and P-1) and the N-terminal
residue of the natural ligand (P1) to ERAP1 was com-
puted by assigning a score ranging from 0 to 100 to each
residue, based on its cleavage efficiency. The mean
scores for peptides within each subset at P-2, P-1, and P1
were compared (Table 2). The mean susceptibility of the
flanking residues to ERAP1 observed in the 3 pairwise
comparisons was very similar regardless of the IR subset
being considered. Moreover, no differences in the mean
susceptibility of P1 residues were observed in the
C1R05/P50 comparison. In contrast, in LG2/P50 and
LG2/C1R05, a higher susceptibility of the P1 residues
from P50- or C1R05-derived peptides relative to LG2
was observed when the IR 3 subsets were compared,
but not among peptides with similar abundance (IR
1–3).
Thus, we analyzed in more detail the frequency of
P1 residues, based on their susceptibility to ERAP1. For
each pairwise comparison, the joint frequencies of P1
residues with high (score of50), intermediate (score of
21–49), or low (score of 0–20) susceptibility in each
peptide subset were compared (Figure 3). The peptides
from the IR 3 subsets in LG2/P50 and LG2/C1R05
showed statistically significant differences in the usage of
P1 residues with intermediate and low scores, but not
high scores (Figures 3A and B). P1 residues with inter-
mediate susceptibility were less abundant, and those
with low susceptibility more abundant, among those
peptides predominant (IR3) in the context of the most
active ERAP1 variant (LG2), relative to the less active
Table 2. Susceptibility of N-terminal flanking and P1 residues of
B*27:05 ligands to ERAP1
Comparison,
peptides*
ERAP1 susceptibility score†
P-2 P-1
P-2 
P-1 P1
P50/LG2
IR 3
70/49 24.1/28.3 53.5/42.8 77.5/70.1 27.9/16.5
Mean score ratio 0.9 1.3 1.1 1.7‡
IR 1–3
57/62 28.5/34.1 47.2/45.2 74.2/78.5 24.1/19.8
Mean score ratio 0.8 1.0 1.0 1.2
C1R05/LG2
IR 3
101/52 37.5/34.9 42.5/43.3 78.9/78.2 28.4/17.0
Mean score ratio 1.1 1.0 1.0 1.7‡
IR 1–3
50/52 30.3/37.4 46.6/40.9 76.3/78.3 26.4/23.4
Ratio 0.8 1.1 1.0 1.1
P50/C1R05
IR 3
74/63 36.1/34.6 41.9/39.6 77.2/73.3 29.7/29.0
Mean score ratio 1.0 1.1 1.1 1.0
IR 1–3
76/61 31.5/37.5 46.2/47.8 77.1/84.1 23.5/26.6
Mean score ratio 0.8 1.0 0.9 0.9
* Peptides shared among any 2 cell lines were classified according to
the relative intensity of the corresponding ion peak in both cell lines.
This was designated as the intensity ratio (IR), which is categorized
here as 3-fold or 1–3-fold. Shown are the number of peptides
sequenced from the indicated subset in each cell line.
† Mean susceptibility score for the corresponding residues at the
indicated positions in each peptide subset of the 2 cell lines being
compared: the 2 N-terminal flanking residues (P-2 and P-1) and the
N-terminal residue of the natural ligand (P1) of ERAP1.
‡ P  0.05 by chi-square test, between the susceptibility scores of the
corresponding peptides.
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ones (P50 and C1R05). The same tendency was ob-
served among peptides with an IR of 1–3 in both
comparisons, although these differences did not reach
statistical significance. No difference in the susceptibility
of P1 residues to ERAP1 was observed in the C1R05/
P50 comparison (Figure 3C).
These results indicate that the ERAP1 polymor-
phism K528R alters the B*27:05-bound peptidome by
regulating epitope destruction as a function of the
susceptibility of the P1 residues of HLA–B27 ligands to
trimming. The observed patterns suggest that highly
susceptible residues are efficiently trimmed by all
ERAP1 variants, leading to a similar destruction of the
corresponding epitopes. P1 residues with intermediate
susceptibility are more efficiently cleaved by the most
active variant, resulting in their higher frequency among
the predominant peptides in a less active ERAP1 con-
text. The increased frequency of ERAP1-resistant P1
residues among HLA–B27 ligands that are predominant
in a more active context is the logical consequence of the
higher destruction of peptides with more susceptible P1
residues, together with limited digestion of resistant
ones even by the most active variant.
Little influence of the differential activity of
ERAP1 variants on the length of HLA–B27 ligands. The
differences in molecular weight among B*27:05 ligands
predominant in distinct ERAP1 contexts could be due to
differential residue usage, differential length, or both.
Thus, we compared the mean molecular weight and
length distributions of the peptides sequenced from the
IR 3 subsets in the LG2/P50 and LG2/C1R05 compar-
isons. In LG2/P50, the predominant peptides sequenced
from LG2 (n 	 49; mean MW 1169.4 daltons and mean
length 9.5 residues) and those from P50 (n 	 70; mean
MW 1094.5 daltons and mean length 9.3 residues)
showed a MW of 74.9 daltons. For LG2/C1R05, the
predominant peptides sequenced from LG2 (n 	 52;
mean MW 1195.7 daltons and mean length 9.6 residues)
and those from C1R05 (n 	 101; mean MW 1118.9
daltons and mean length 9.3) showed a MW of 76.8
daltons. These differences were only slightly higher than
those observed in the global peptide comparisons (Fig-
ure 2 and Supplementary Table 2, available on the
Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38980/abstract), sug-
gesting that the sequenced peptides are representative
Figure 3. ERAP1 susceptibility of the P1 residues from B*27:05 ligands showing differential abundance among the cell lines studied. The frequency
of P1 residues with high (score of 50; A, C, L, M, and Y), intermediate (Int.) (score of 21–49; F, G, H, I, N, Q, S, and T), and low (score of 0–20;
D, E, K, P, R, V, and W) susceptibility to ERAP1 trimming among the peptides sequenced from LG2 and P50 (A), LG2 and C1R05 (B), and C1R05
and P50 (C) from their corresponding intensity ratio (IR) subset (3 [top] or 1–3 [bottom]) in the corresponding pairwise comparison was
determined. Statistically significant (P  0.005) differences among the individual residues, as determined by chi-square test, are specified.
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of their respective IR subsets. Yet, they showed very
similar length distribution (Figure 4A).
The results indicate that the molecular weight
differences among B*27:05 ligands are due to differen-
tial residue usage and not to distinct peptide length. As
expected, in C1R05/P50, the predominant peptides se-
quenced from C1R05 (n	 63; mean MW 1127.1 daltons
and mean length 9.5 residues) or P50 (n 	 74; mean
MW 1134.4 daltons and mean length 9.6 residues)
showed essentially no differences in either mean molec-
ular weight or length.
Influence of residues downstream of the
N-terminus on the processing of HLA–B27 ligands in an
ERAP1 variant–dependent way. To determine the struc-
tural basis for the observed molecular weight differ-
ences, we selected the 9-mers from the IR 3 subsets in
the LG2/P50 and LG2/C1R05 comparisons, since they
accounted for 70% of the sequenced peptides from
each subset (Figure 4A). The mean molecular weight
between the predominant 9-mers sequenced from LG2
(1107.6 daltons) and P50 (1060.8 daltons) was 46.8
daltons higher for LG2. This was due to moderate
differences in the mean residue mass along multiple
positions, mainly P1, P3, P4, P8, and P9 (Figure 4B). For
LG2/C1R05, the mean molecular weight between the
predominant 9-mers sequenced from LG2 (1138.8 dal-
tons) and C1R05 (1081.5 daltons) was 57.3 daltons
higher in LG2. Once again, this difference was due to
the contribution of multiple positions, but now P1
(residual mass 29.8 daltons) accounted for 52% of the
total. In C1R05/P50, the predominant 9-mers showed
essentially no difference in their mean molecular weight:
1070.7 daltons and 1071.7 daltons, respectively.
Thus, the P1 residue only partially accounts for
the molecular weight differences induced in the HLA–
B27 peptidome by ERAP1 variants. Our results reveal
an additional contribution of the sequence downstream
of the N-terminus on the shaping of the peptidome by
ERAP1 allotypes differing at K528R. An overall ten-
dency toward bulkier residues at multiple positions was
observed among HLA–B27 ligands predominant in the
most active ERAP1 context (K528) of LG2 cells.
DISCUSSION
In vitro studies with ERAP1 mutants demon-
strated that the disease-protective changes R528
(2,8,14,26,27,29) and Q725 (2,14) decreased the enzy-
matic activity, whereas N575 increased ERAP1 activity
in 2 studies (14,26), but had no effect in others in which
either 1 substrate (2) or 2 substrates (27) were examined.
This apparent discrepancy may be due to the fact that
the effect of a given polymorphism on peptide trimming
is dependent on both its structural context and the
substrate tested. By appropriate choice of the ERAP1/
ERAP2 background of 3 B*27:05-positive cell lines, we
analyzed the effect of the K528R mutation in the
presence (LG2/P50) or absence (LG2/C1R05) of the
D575N/R725Q changes on the B*27:05 peptidome. In
addition, the P50/C1R05 comparison allowed us to
address the effect of D575N/R725Q in the absence of
polymorphism at residue 528.
This study did not address the presence or ab-
sence of specific ligands in a variant-dependent way,
since MS analyses cannot formally establish the absence
of a peptide. Our purpose was to define global effects on
the amount of shared peptides as a function of ERAP1
polymorphism, since quantitative changes may signifi-
cantly affect the biologic behavior of HLA–B27. Specific
HLA–B27 epitopes produced only in particular ERAP1
contexts are likely to exist and might be relevant for AS,
but these should be investigated separately.
The ME1 antibody that was used to purify HLA–
Figure 4. Length distribution and residual mass differences among
B*27:05 ligands showing differential abundance among the cell lines
studied. A, Length distribution among the sequenced peptides pre-
dominant (intensity ratio [IR] 3) in LG2 and P50 (top) or LG2 and
C1R05 (bottom) in the corresponding pairwise comparisons. B, Mean
differential mass (residual mass) at the indicated positions between
residues of the B*27:05 ligands predominant (IR 3) in LG2 and P50
(top) or LG2 and C1R05 (bottom) in the corresponding pairwise
comparisons.
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B27 recognizes the bulk of B27–peptide complexes.
Although it is formally impossible to exclude the possi-
bility that some HLA–B27 ligands might be overlooked
with this or any other antibody, there is no evidence that
ME1 might be reacting with a particular fraction of the
peptidome. In a previous study, in which both ME1 and
the anti–MHC class I antibody W6/32 were used, no
significant differences in the length or P1 residue fre-
quencies of the HLA–B27 ligands were observed (30).
Our experimental approach was based on
MALDI-TOF MS. The use of this technique for com-
paring MHC class I–bound peptidomes has been dis-
cussed in detail elsewhere (13). It will only be empha-
sized here that it is a powerful and reproducible way to
reveal collective tendencies within large sets of peptides.
This was clear from the reproducibility of the molecular
weight distribution patterns among subsets of HLA–B27
ligands, which were classified according to their relative
ion peak intensities, across individual experiments. Yet,
MALDI-TOF MS is not quantitative and cannot be
applied to quantify differences in expression on an
individual peptide basis.
Our results revealed that in the cell lines exam-
ined, the AS-protective K528R mutation had a substan-
tial effect on the B*27:05 peptidome that was indepen-
dent of residues 575/725. In addition, in the absence of
polymorphism at residue 528, a mismatch at 575/725 had
little effect. Since natural variants contain multiple
changes in strong linkage disequilibrium, K528/R127
and R528/P127 co-occurred in our cell lines. Thus,
although we cannot unambiguously assign to one of
these mutations the observed peptide differences be-
tween LG2 and C1R05 or P50, it is very likely that they
are mainly due to K528R, since R127P has little effect
on ERAP1 activity (27). D575N/R725Q co-occurred
with M349V in P50. In one study (14), M349V/D575N/
R725Q did not alter ERAP1 activity, which is consistent
with the absence of significant peptidome alterations
across these 3 differences in C1R05/P50. The same study
reported that in the context of M349, D575N/R725Q
decreased ERAP1 activity. Thus, the possibility that in
the absence of M349V, the D575N/R725Q changes
might have a larger effect on the HLA–B27 peptidome
cannot be ruled out.
Since the two cell lines carrying R528 differed
2-fold in the expression levels of ERAP1, we cannot
exclude the possibility that higher expression on P50
relative to C1R05 might obscure a potentially higher
activity of the ERAP1 variant in the latter cell line,
which carries the AS-predisposing residues D575/R725.
This possibility would also explain the finding that LG2
showed comparable differences in the B27-bound pep-
tidome with both cell lines, since a putatively higher
activity of the ERAP1 variant in C1R05 might be
compensated by its lower expression. A differential
influence of ERAP2 in our cell lines can be excluded,
since all expressed the K392 variant and showed similar
enzyme levels. A contribution of puromycin-sensitive
aminopeptidase, an enzyme involved in post-
proteasomal processing, to the observed peptide differ-
ences is also unlikely based on concordance of the 3 cell
lines at the AS-associated marker rs9901869.
An interesting issue concerns the higher expres-
sion of ERAP1 in LG2 (K528) relative to that in C1R05
and P50 (R528). A correlation between the strength of
the single-nucleotide polymorphism association with AS,
including rs30187 (coding for residue 528), and the
strength of the association with ERAP1 transcript abun-
dance has been reported (24). Constantino and col-
leagues (25) subsequently observed that the risk haplo-
type of ERAP1 in AS, including K528, is associated with
higher ERAP1 protein expression in EBV-transformed
cell lines, which we confirmed in an independent panel
of HLA–B27–positive and HLA–B27–negative cell lines
(Martin-Esteban A, et al: unpublished observations).
Higher expression of the most active ERAP1 variants
may be a mechanism by which to enhance the effect of
increased enzymatic activity induced by an AS-
predisposing polymorphism.
Peptide sequencing revealed the basis for the
alterations in the B*27:05 peptidome induced by the
ERAP1 polymorphism. The higher frequency of
ERAP1-resistant P1 residues among predominant li-
gands in LG2 (K528), relative to those predominant in
less active (R528) contexts, reflects a larger destruction
of ligands with ERAP1-sensitive P1 residues by the more
active variant. This was shown by increased expression of
these peptides in the less active contexts (C1R05 and
P50). Seregin et al (31) recently noted that highly active
ERAP1 variants carrying AS-predisposing polymor-
phisms, including K528, led to reduced expression of
multiple HLA–B27 ligands due to increased epitope
destruction, which is consistent with our results. Yet, as
shown here, ERAP1 variants with K528 also induced the
increased expression of other peptides, relative to the
less active allotypes. This is explained by the fact that
MHC ligands with ERAP1-resistant P1 residues are
more efficiently generated by a more active variant but
are not extensively destroyed even in this context. In-
creased yields of HLA–B27 ligands by ERAP1 variants
with lower activity, relative to more active ones, have
been directly demonstrated in vitro (26).
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The molecular weight differences observed
among peptides predominant in the context of ERAP1
variants with K528 or R528 were not due to differential
peptide length, but to the higher frequency of bulkier P1
and other residues in the more active context. This is
consistent with the influence of peptide sequences
downstream of the N-terminus on ERAP1 trimming (32)
and further indicates an ERAP1 variant–dependent
influence of such sequences. Our results suggest that
higher occupancy of the substrate-binding site of
ERAP1 by bulkier peptides may favor the structural
rearrangement required for efficient peptide trimming
as a function of residue 528. This is located in an
interdomain region that is critical for the conformational
transition to the active state (7,8).
Our previous findings in B*27:04 (13) showed
significant differences in the length of HLA–B27 ligands
in the distinct ERAP1 contexts examined. There, the
most active and the less active ERAP1 allotypes differed
by the same mismatches as LG2 and P50, plus Q730E. In
contrast, all of the variants in the present study had
E730. Thus, the length-dependent effects observed in
B*27:04, but not B*27:05, might be at least partially
determined by residue 730. In vitro experiments using
poly-Gly peptides of increasing lengths show that poly-
morphism at position 528 was not sensitive to substrate
length, whereas the relative activity of ERAP1 variants
differing at position 730 was substrate length-dependent
(Stratikos E: personal communication), which is consis-
tent with our observations.
The substantial effects of the AS-predisposing
polymorphism at residue 528 on the HLA–B27 pep-
tidome can influence the biology of HLA–B27 in multi-
ple ways. As previously suggested (31), increased
epitope destruction in an active ERAP1 context could
render HLA–B27 unable to present certain antigens.
This might confer a certain degree of immunodeficiency
to HLA–B27–positive individuals that might interfere
with the immune control of microorganisms and tumor
cells. Increased presentation of a specific tumor antigen
upon down-regulation of the ERAP1 ortholog, which
leads to improved tumor control, was observed in a
murine colorectal carcinoma (33). Yet, the fact that
many peptides were expressed in higher amounts in a
more active ERAP1 context indicates that increased
presentation of other epitopes by HLA–B27 also takes
place with AS-predisposing variants.
ERAP1-dependent changes in the HLA–B27
peptidome may also alter T cell repertoire selection,
which is dependent on epitope amounts (34), and mod-
ulate the tolerogenic/autoimmune potential of HLA–
B27, affecting the capacity of individuals to respond to,
or be tolerized against, particular epitopes even if pre-
sented by other MHC molecules. This phenomenon was
recently documented in transgenic mice, where coex-
pression of B7 and B27 resulted in suppression of the
HLA–B27–restricted response against a flu-derived
epitope through a mechanism involving the negative
selection of relevant T cells (35). Aside from its specif-
ically immunologic effects, ERAP1 polymorphism may
affect other peptide-dependent properties of HLA–B27,
such as its thermostability (13) or the expression of free
heavy chains at the surface of certain cell types (36).
The mechanism of association of ERAP1 with AS
is based on altering in a global and significant way the
HLA–B27 peptidome through differential effects on the
generation/destruction balance of many epitopes, de-
pending on the allelic ERAP1 activity and the
N-terminal and other residues of the natural ligands.
Due to these alterations, the immunologic and other
potentially pathogenic features of HLA–B27 can be
substantially affected by ERAP1 polymorphism.
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